Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

This study tests artesunate vaginal inserts — a medication derived from a malaria drug — as a treatment for high-grade precancerous lesions on the cervix (called CIN2 or CIN3). These lesions are caused by HPV infection and, if untreated, can develop into cervical cancer. **You may be eligible if...** - You are a woman aged 25 or older - You have been diagnosed with CIN2, CIN3, or CIN2/3 confirmed by biopsy - You have a detectable HPV infection - You weigh at least 50 kg - You agree to use birth control during the study **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have an active autoimmune disease - You are taking immunosuppressive medications - You are HIV-positive or have a weakened immune system - You have cervical adenocarcinoma in situ (a different type of precancer) or another active cancer Talk to your doctor to see if this trial is right for you.